#foundayo

7 articles tagged #foundayo.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

Editorial lifestyle photograph illustrating a morning wellness routine with a glass of water on a clean kitchen counter
GuideComparisonsJune 22, 202610 min read

Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only, not weight loss.

Editorial still-life illustrating Foundayo and Wegovy pill comparison for weight loss
AnalysisComparisonsJune 16, 202620 min read

Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss, $149 vs $1,349/mo Self-Pay

Updated June 16, 2026: CVS Caremark removed Foundayo's new-to-market block June 1 (~25–30M commercial lives can now be covered); Zepbound becomes co-preferred Oct 1; Medicare GLP-1 Bridge covers Foundayo at $50/mo from July 1. Verified IQVIA launch data runs through Week 3 (1,390 → 3,707 → 5,612 Rx); later weeks are competing analyst estimates (Citi ~16,000 vs Jefferies ~11,700 for late May) that undercount telehealth. Oral Wegovy produces 16.6% weight loss vs Foundayo's 12.4%; Foundayo starts at $149/mo self-pay with no fasting requirement.

Editorial still-life illustrating the Medicare GLP-1 Bridge enrollment process and access to weight-loss medication
GuideCost & InsuranceJune 11, 202616 min read

Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Editorial lifestyle photograph illustrating a guide to Foundayo orforglipron oral GLP-1
GuideGuidesApril 29, 202614 min read

Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions, take any time.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

TrimRx

7.8/10
$149/mo·Compounded

SkinnyRx

7.3/10
$199/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.